Market News AIOpen the app

Bristol Myers Squibb's Zenbexus helps blood cancer patients, lowering the chance of disease worsening by 51%.

TrialRead the original at Benzinga
Good for BMY

Bristol-Myers Squibb reported that Zenbexus cut the risk of cancer progression or death, supporting its use in multiple myeloma. The safety profile matched earlier findings, so the report adds no new safety concern.

BMY · Bristol-Myers Squibb

AI read · Good for BMY

The AI's read

A longer period before the cancer worsened could make Zenbexus more useful after a first relapse. Its FDA approval is already in place, and these results add support for its use. The reported safety profile matched earlier findings, so the report raises no new safety concern.

Get alerts for BMY

Follow Bristol-Myers Squibb (BMY) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for BMY
Free on the App Store and Google Play, or on the web.